A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

January 19, 2022

Study Completion Date

January 19, 2022

Conditions

Cutaneous T Cell LymphomaMycosis FungoidesSezary Syndrome

Interventions

DRUG

[14C]-resminostat

1 single dose of 400 mg \[14C\]-resminostat

Trial Locations (1)

Covance Clinical research Unit Ltd., Leeds

All Listed Sponsors

lead

4SC AG

INDUSTRY

NCT04955340 - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | Biotech Hunter | Biotech Hunter